U.S. NEWS
02/11/2018 03:10 pm ET

OxyContin Drugmaker Vows To Stop Promoting Opioids To Doctors

Purdue Pharma also said it will cut its sales force by about half.

The maker of painkiller OxyContin will stop promoting opioid drugs to doctors and will slash its sales force by half, a decision that follows the company receiving a barrage of lawsuits that cite the ongoing opioid epidemic.

Drug manufacturer Purdue Pharma, in a statement released on Saturday, said its remaining 200 sales representatives will no longer visit doctors’ offices to advertise the highly addictive painkillers.

“We have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers,” the Connecticut-based company said in a statement obtained by Reuters.

Purdue Pharma, which manufactures the prescription painkiller OxyContin, has said that it will no longer be promoting opioids
George Frey / Reuters
Purdue Pharma, which manufactures the prescription painkiller OxyContin, has said that it will no longer be promoting opioids at doctors' offices.

The decision comes after states, cities and counties filed lawsuits against Purdue Pharma and other companies, accusing them of fueling the opioid epidemic by favoring profits over human health.

Opioids, including prescription opioids, heroin and fentanyl, killed more than 42,000 people in 2016, the highest death toll ever recorded, according to the Centers for Disease Control and Prevention.

Nearly half of those deaths, at around 40 percent, involved a prescription opioid, the CDC said.

OxyContin, Purdue Pharma’s biggest-selling drug, generated the company $1.8 billion in 2017 ― down from $2.8 billion five years earlier, Bloomberg reported citing market researcher Symphony Health Solutions.

Purdue Pharma has defended its business practices, arguing that the U.S. Food and Drug Administration approved its drugs, which account for only 2 percent of all opioid prescriptions.

HuffPost

BEFORE YOU GO

PHOTO GALLERY
27 Reasons Why U.S. Shouldn't Lead War On Drugs
CONVERSATIONS